

DAFTAR PUSTAKA

- Alianto, R. 2015. Gambaran Histopatologi Karsinoma Hepatoseluler. *Cermin Dunia Kedokteran*, 42(6), 440–444.
- Amirudin, A. 2014. Fisiologi dan Biokimia Hati. *dalam*: S. Setiati, I. Alwi, A.W. Sudoyo, M. Simadibrata, B. Setiyohadi, A.F. Syam (editors). *Buku Ajar Ilmu Penyakit Dalam*. Jilid I. Edisi VI. Internal Publishing. Pusat Informasi dan Penerbitan Departemen Ilmu Penyakit Dalam FKUI. 3040-3046
- Arnadi, Suryadhana, N.G., Kasjmir, Y.I. 2014. Pemeriksaan *C-Reactive Protein*, Faktor Reumatoid, Autoantibodi dan Komplemen. *dalam*: S. Setiati, I. Alwi, A.W. Sudoyo, M. Simadibrata, B. Setiyohadi, A.F. Syam (editors). *Buku Ajar Ilmu Penyakit Dalam*. Jilid III. Edisi VI. Internal Publishing. Pusat Informasi dan Penerbitan Departemen Ilmu Penyakit Dalam FKUI. 3105-3106.
- Bertino, G., Demma, S., Bertino, N., Ardori, A. 2014. Management of Hepatocellular Carcinoma: An Update at the Start of 2014. *J Gastroint Dig Syst*. 4:178
- Bhagavan, N.V. 2002. Simple Carbohydrates. *Medical Biochemistry* (Fourth Edition).
- Budihusodo, U. 2014. Karsinoma Hati. *dalam*: S. Setiati, I. Alwi, A.W. Sudoyo, M. Simadibrata, B. Setiyohadi, A.F. Syam (editors). *Buku Ajar Ilmu Penyakit Dalam*. Jilid I. Edisi VI. Internal Publishing. Pusat Informasi dan Penerbitan Departemen Ilmu Penyakit Dalam FKUI. 3040-3046
- Carr, BI, Akkiz, H, Guerra V, Uskudar, O, Kuran, S, Karaogullarindan U, et al. 2018. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors. *Clin Pract (Lond)*. 15: 625-634
- Chandrashekhara S. 2014. C-reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. *Internet journal of rheumatology and clinical immunology*, Vol 2
- Chen, W., Wang, J., Abnet, C.C., Dawsey, S.M., Fan, J., Yin, L., ... Freedman, N. D. 2016. Association between C-reactive protein, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. *Cancer Epidemiol Biomarkers Prev*. 386–392.
- Cheng, H., Chang, Y., Chen, Y., Lee, T., Tai, D., Lin, D. 2007. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. *J Chin Med Assoc*. 70(8):310-317
- Choi, J.Y., Jung, S.W., Kim, H.Y., Kim, M., Kim, Y., Kim, D.G., Eun-Jee Oh. 2013. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular

- carcinoma according to total-AFP. *World J Gastroenterology*. 19(3): 339-346
- Choi K, Hong S, Chang Y, Lee W, Paik I, Lee H. (2014) Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal patients. *Annals of Surgical Treatment and Research Journal* ; 309-313
- Dufour, M. 2013. C-Reactive Protein, a Prognostic Marker in Hepatocellular Carcinoma. *HEPATOLOGY*, 57(6), 2103–2105.
- El-Serag, H.B. 2012. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. *Gastroenterology*. 142(6):1264–1273
- Fox, R., Berhane, S., Teng, M., Cox, T., Tada, T., Toyoda, H. 2014. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. *British Journal of Cancer*. 110;2090-2098
- Gopal, P., Yopp, A., Waljee, A., et al. 2014. Factors That Affect Accuracy of Alpha Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. *Clin Gastroenterol Hepatol*. 12:870–877
- Hashem, B., El-Serag. 2013. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma NIH Public Access. *Gastroenterology*, 142, 1264–1273.
- Huang, T., Shyu, Y., Turner, R., Chen, H., Chen, P. 2013. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. *Biomed Central*. 2:37
- Jin, K., Li, T., Sanchez, G., Zhou, F., Zhang, L. 2016. Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. *Oncotarget*. (11):1-22
- Jun, C.H., Ki, H.S., Lee, K.H., Park, K.J., Park, S.Y., Cho, S.B., & Park, C.H. 2013. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. *Clinical and Molecular Hepatology*, 19, 70–77.
- Juwita, R. 2017. Kadar C-reaktif protein sebagai prediktor faktor mortalitas pada pasien karsinoma hepatoseluler dengan sarkopenia (tesis). Universitas Gadjah Mada, Yogyakarta.
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., Tajiri, H. 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World J Hepato*. 7(3):406-424
- Kumada, T., Toyoda, H., Tada, T., Kiriyaama, S., Tanikawa, M., Hisanaga, Y., et al. 2014. High-sensitivity Lens culinaris agglutinin-reactive

alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. *Japan Soc Gastroenterol.* 49:555-563

Kusuma, I.,F. 2019. Rasio *alpha fetoprotein-L3/alpha fetoprotein* (AFP-L3%) sebagai faktor prediktor mortalitas pasien dengan karsinoma hepatoseluler di RSUP Dr. Sardjito (tesis). Universitas Gadjah Mada, Yogyakarta.

Lavanchy, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepatitis.* 11:97-107

Lazarevich, N.L. 2012. AFP (alpha-fetoprotein). *Atlas of Genetics and Cytogenetics in Oncology and Haematology.* 17(1).

Leerapun, A., Suravarapu, S.V., Bida, J.P., *et al.* 2007. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. *Clin Gastroenterol Hepatol.* 5: 394-402

Lesmana, L.A., Waspodo, A.S., Gani, R.A., Hasan, I., Siregar, L., Sulaiman, A.S., *et al.* 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Perhimpunan Peneliti Hati Indonesia. Perhimpunan Dokter Spesialis Patologi Indonesia. Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia. Perkumpulan Subspesialis Radilogi Abdomen Indonesia. Perhimpunan Dokter Spesialis Bedah Digestif Indonesia

Li, B., Li, B., Guo, T., Sun, Z., Li, X., Li, X., *et al.* 2017. The clinical values of serum markers in the early prediction of hepatocellular carcinoma. *BioMed Research International.* 1-11

Li, D., Mallory, T., Satomura, S. 2001. AFP-L3 : a new generation of tumor marker for hepatocellular carcinoma. *Clinica Chimica Acta.* 313(1): 15-19

Lopez,J.,B.2005.Recent Developments in the First Detection of Hepatocellular Carcinoma. *Clin Biochem Rev* (26) :65-79

Mittal, S., El-Serag, H.,B. 2013. Epidemiology of HCC: Consider the Population. *J. clin Gastroenterol.* 47(0):S2-S6

Morimoto, M., Numata, K., Nozaki, A., Kondo, M., Moriya, S., Taguri, M., *et al.* 2012. Novel Lens culinaris agglutinin-reactive fraction of α -fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α -fetoprotein concentrations. *Int J Clin Oncol.* 17:373-379

Oka, H., Saito, A., Ito, K., *et al.* 2001. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of *Lens culinaris* agglutinin-reactive α -fetoprotein. *J Gastroenterol and Hepatol* 16:1378–1383

Omata, M., Lesmana, L.A., Tateishi, R., Lin, P.C.S., & Yoshida, H. 2010. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int,* 4, 439–474.

- Peng, S., Chen, W., Lai, P., et al. 2004. High α -Fetoprotein Level Correlates With High Stage, Early Recurrence And Poor Prognosis Of Hepatocellular Carcinoma: Significance Of Hepatitis Virus Infection, Age, P53 And β -Catenin Mutations. *Int. J. Cancer*. 112: 44–50
- Pinato, D.J., North, B.V, & Sharma, R. 2012. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma : the prognostic nutritional index (PNI). *British Journal of Cancer*, 106(8), 1439–1445.
- Pons, F., Varela, M., & Llovet, J.M. 2005. Staging systems in hepatocellular carcinoma. *HPB*, 7, 35–41.
- Rekik, S., Guyot, E., Bhais, M., Ajavon, Y., Grando, V., Bourcier, V., Nault, J. 2016. The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. *Digestive and Liver Disease*, 6–10.
- Saffroy, R., Lemoine, A., Debuire, B. 2007. Mechanism of Hepatocarcinogenesis. *Atlas of Genetics and Cytogenetics in Oncology and Haematology*. 11(1):65-68
- Schwartz, M.J. 2009. Clinical features and diagnosis of primary hepatocellular carcinoma. UpTo date version 21.2
- Sean, F.A., Katherine, A.M., Marsha, E.R. 2009. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975-2005. *J Clin Oncol*. 27(9):1485-1491
- Setsu, T., Tsuchiya, A., Watanabe, T., Nagoya, T., et al. 2017. Early Detection of Hepatocellular Carcinoma Recurrence Using the Highly Sensitive Fucosylated Fraction of Alpha-Fetoprotein. *Case Rep Gastroenterol*. 11:142–147
- Shin, J.H., Kim, C.J., Jeon, C.J., Sung, C.O., Shin, H.J., Choi, J., Yu, E. 2015. Overexpression of C-reactive protein as a poor prognostic marker of resectable hepatocellular carcinoma. *J Pathol Transl. Med*. 49 (2):105-11
- Singhal, A., Jayaraman, M., Dhanasekaran, D.N., Kohli, V. 2012. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. *Crit Rev Oncol Hematol*. 82: 116-140
- Siregar, G.A. (2011). Penatalaksanaan non bedah dari karsinoma hati. *Universa Medicina*, 24(1), 35–42.
- Suprianata, I.M., Sudania, W.M., Tjong, W.Y., Suciptan, A.A., Gani, R.A., Hasan, I., et al. 2010. Alpha-feto-protein gene polymorphisms and risk of HCC and cirrhosis. *Clinica Chimica Acta*. 411:351-358
- Tada, T, Kumada, T., Toyoda, H., et al. 2005. Relationship between Lens culinaris agglutinin-reactive a-fetoprotein and pathologic features of hepatocellular carcinoma. *Liver International*. 25: 848–853

- Toyoda, H., Kumada, T., Tada, T., Kaneoka, Y., Maeda, A., Kanke, F., Satomura, S. 2011. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20ng/mL. *Japan Cancer Assoc.*102(5);1025-1031
- Toyoda, H., Kumada, T., Tada, T., et al. 2015. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. *Liver Cancer.* 4:126–136
- Waghray, A., Murali, A.R., Menon, K.V. 2015. Hepatocellular carcinoma: from diagnosis to treatment. *World J Hepatol.* 7(8):1020-1029
- Wang, C.S., Sun, C.F. 2009. C-reactive protein and malignancy: Clinico-pathological Association and Therapeutic Implication. *Chang Gung Med J.* 32(5): 471-478
- Wang, X., Wang, Q. 2018. Alpha Fetoprotein and Hepatocellular Carcinoma Immunity. *Canadian Journal of Gastroenterology and Hepatology.* 4:1-8
- Wong, R., and Corley, D.A. 2008. Racial and ethnic variations in hepatocellular carcinoma incidence within the Unites States. *Am J Med.* 121:525-531
- Yao, D.F., Zhi-Zhen Dong, Min Yao. 2007. Specific molecular marker in Hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int;* 6(3):15-22
- Yi, X., Yu, S., Bao, Y. 2013. Alpha-fetoprotein-L3 in hepatocellular carcinoma: A meta-analysis. *Clinica Chimica Acta.* 425:212-220
- Zhao, Y., Ju, Q., Li, G. 2013. Tumor markers for hepatocellular carcinoma (review). *Mol Clin Oncol.* 1:593-598
- Zheng, Z., Zhou, L., Gao, S., Yang, Z., & Zheng, S. 2013. Prognostic role of C-Reactive Protein in Hepatocellular Carcinoma : A Systematic Review and Meta-Analysis. *International Journal of Medical Sciences,* 10(6), 653–664.
- Zhu, R.X., Seto, W., Lai, C., & Yuen, M. 2016. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut and Liver,* 10(3), 332–339.